InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Present Alzheimer’s Advances at AAIC 2025 in Toronto
June 26, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical company focused on therapies for neurodegenerative diseases, announced its leadership will attend the Alzheimer’s Association International Conference (AAIC) from July 27–31, 2025, in Toronto. The company will present four scientific posters detailing progress on its Alzheimer’s clinical program and pharmacokinetic data for its lead candidate, buntanetap. Topics include […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Gains 18-Month NYSE Compliance Window
June 20, 2025
Annovis Bio (NYSE: ANVS), a clinical-stage platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, has received formal acceptance from the New York Stock Exchange of its compliance plan addressing minimum market capitalization and stockholders’ equity requirements. The NYSE granted the company an 18-month window, beginning March 26, 2025, to regain compliance. During […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Host Webcast With CEO to Share Updates on Alzheimer’s and Parkinson’s Programs
June 5, 2025
Annovis Bio (NYSE: ANVS) announced it will host a live webcast on June 24, 2025, at 4:30 PM EDT, featuring President and CEO Maria Maccecchini, Ph.D. The event will provide updates on the company’s pivotal Phase 3 trial for early Alzheimer’s disease, recent FDA feedback on its Parkinson’s disease program, and other key initiatives. The […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Advances Phase 3 Alzheimer’s Trial and Expands Conference Presence in Q1
May 14, 2025
Annovis Bio (NYSE: ANVS) initiated its pivotal Phase 3 clinical trial in early Alzheimer’s disease during Q1 2025, with enrollment now underway for up to 760 participants to assess buntanetap’s symptomatic and disease-modifying effects over 18 months. The company also secured a new U.S. patent for buntanetap and participated in several key scientific and investor […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Appoints Hui Liu as Director of Biostatistics
April 29, 2025
Annovis Bio (NYSE: ANVS), announced the appointment of Hui Liu as Director of Biostatistics as the company advances its pivotal Phase 3 Alzheimer’s disease trial. Liu brings over 19 years of experience in clinical trial design, analysis and regulatory submission support across multiple therapeutic areas. Annovis stated that Liu’s expertise will help reinforce the scientific […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Receives NYSE Noncompliance Notice Over Market Cap and Equity Levels
March 28, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on therapies for neurodegenerative diseases, disclosed it received a noncompliance notice from the New York Stock Exchange on March 26, 2025, for falling short of continued listing standards under Section 802.01B. The notice stated that the company’s average global market capitalization over a 30-day […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Present Late-Stage Alzheimer’s and Parkinson’s Data at AD/PD 2025
March 25, 2025
Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company focused on neurodegenerative diseases, will present key data from its Phase 3 Parkinson’s and Phase 2/3 Alzheimer’s studies at the AD/PD™ 2025 conference in Vienna from April 1–5. Presentations will highlight buntanetap’s impact on cognition and motor function in early Parkinson’s patients, and its advantages for […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Advances Alzheimer’s and Parkinson’s Pipeline, Launches Pivotal Phase 3 Trial
March 24, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, reported fourth quarter and full year 2024 results, highlighting major milestones in its buntanetap program for Alzheimer’s and Parkinson’s disease. The company completed two key trials last year, showing cognitive and motor improvements, leading to FDA clearance for a pivotal Phase 3 trial in early […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Present at Alzheimer’s & Parkinson’s Drug Development Summit
March 11, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on neurodegenerative diseases, will participate in the 13th Alzheimer’s & Parkinson’s Drug Development Summit from March 18-20 in Boston. CEO Maria Maccecchini, Ph.D., will present Phase III data on buntanetap and discuss a holistic approach to targeting neurotoxic proteins on March 19. Annovis will […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Host Patient Forum on Alzheimer’s and Parkinson’s Trials
February 19, 2025
Annovis Bio (NYSE: ANVS) will host a live webcast on Feb. 27, 2025, at 4:30 p.m. EST, where CEO Maria Maccecchini, Ph.D., will answer questions from patients, caregivers, and families regarding the company’s clinical trials and future plans. The forum will provide updates on the ongoing Phase 3 Alzheimer’s disease trial, plans for the Phase […]
Annovis to Host Patients’ Live Forum on February 27, 2025
February 19, 2025
MALVERN, Pa., Feb. 19, 2025 (GLOBE NEWSWIRE) — via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), will host a live webcast where CEO Maria Maccecchini, Ph.D., will answer questions from patients, […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) CEO to Present at Oppenheimer Healthcare Conference
February 7, 2025
Annovis Bio (NYSE: ANVS) a late-stage clinical drug platform company developing therapies for neurodegenerative diseases, announced that CEO Maria Maccecchini, Ph.D., will present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference on Feb. 11, 2025, from 12:40 to 1:10 p.m. ET. The virtual presentation will cover the company’s progress on its pivotal Phase 3 trial […]
Annovis to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
February 7, 2025
MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that its CEO, Maria Maccecchini, Ph.D., will present at the Oppenheimer’s 35th […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Enrolls First Patients in Phase 3 Alzheimer’s Trial
February 6, 2025
Annovis Bio (NYSE: ANVS) announced that the first two patients have been enrolled in its pivotal Phase 3 trial evaluating buntanetap for early Alzheimer’s disease. The randomized, placebo-controlled study will assess the drug’s symptomatic and potential disease-modifying effects over 18 months. Following positive Phase 2/3 results, the trial received FDA approval and aims to enroll […]
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering
February 6, 2025
MALVERN, PA, Feb. 04, 2025 (GLOBE NEWSWIRE) — via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the closing of its previously announced underwritten public offering of 5,250,000 shares of […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Closes $21M Public Offering to Advance Alzheimer’s Drug Development
February 5, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug company focused on neurodegenerative diseases, announced the closing of its underwritten public offering, raising $21 million in gross proceeds. The offering included 5.25 million shares of common stock and warrants at a combined price of $4.00 per share, with warrants exercisable at $5.00 per share for five […]
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease
February 5, 2025
MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that the first two patients have been entered into the pivotal Phase […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Prices $21 Million Public Offering
February 3, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing treatments for neurodegenerative diseases, has priced an underwritten public offering of 5.25 million shares of common stock and warrants at a combined price of $4 per share. The warrants, exercisable at $5 per share for five years, are expected to generate gross proceeds of […]
Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering
February 3, 2025
MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) — via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the pricing of an underwritten public offering of 5,250,000 shares of common […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures U.S. Patent for Acute Neurodegenerative Treatment
January 14, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, has received a U.S. patent for methods using buntanetap to treat and prevent acute brain and nerve injuries. The patent, issued on Jan. 2, 2025 (US-2025-0000846-A1), covers buntanetap’s ability to reduce neurotoxicity and mitigate neurodegenerative processes in conditions such as stroke, ischemia, traumatic brain injury, […]
Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection
January 13, 2025
MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) — Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it was granted the U.S. patent covering methods for the treatment and prevention of acute […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Streamlined Pathway to Advance Buntanetap for AD
January 7, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), today announced that the FDA has accepted an updated protocol for the pivotal Phase 3 AD study, which is slated to begin in January 2025. In October 2024, the FDA […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Eyes Opportunities Beyond ‘Year of Significant Progress’
December 27, 2024
Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, was featured in a recent article that discussed the company’s year-end investor webcast, where it provided stakeholders with a comprehensive overview of 2024 milestones and strategic initiatives for 2025. The webcast also highlighted financial developments, including the securing of a […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Committed to Ensuring Highest Standards in Continued Buntanetap Trials
December 20, 2024
Annovis Bio (NYSE: ANVS) is a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases. The company’s lead candidate, buntanetap, is an innovative drug that targets multiple pathways involved in neurodegenerative diseases by inhibiting the production of neurotoxic proteins that lead to the death of neurons, thereby slowing or stopping disease progression. A recent […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Eyes Clear Path Forward for Buntanetap
December 16, 2024
Annovis Bio (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, such as Alzheimer’s (“AD”) and Parkinson’s (“PD”). The company concluded the third quarter with the completion of significant milestones and a clear path forward for its lead candidate, buntanetap. “Buntanetap is an innovative drug designed to target neurodegeneration […]
Annovis Bio Inc. (NYSE: ANVS) Showcases 2024 Achievements and Strategic Vision in Year-End Investor Webcast
December 13, 2024
Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company pioneering transformative therapies for neurodegenerative diseases, recently hosted its Year-End Investor Webcast, providing stakeholders with a comprehensive overview of the company’s 2024 milestones and strategic initiatives for 2025. The full webcast is available here: https://youtu.be/NA3kCUZZIpI. During the webcast, Dr. Maria Maccecchini, Founder, President, and CEO of […]
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace
December 5, 2024
LOS ANGELES, Dec. 05, 2024 (GLOBE NEWSWIRE) — via IBN — InvestorBrandNetwork, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce Annovis Bio’s (NYSE: ANVS) recent feature on Today’s Marketplace (TMP) as part of its commitment to amplifying industry leaders’ voices through targeted distribution channels. The full interview can be viewed at https://ibn.fm/m7gvX. […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) CEO Highlights Innovations in Neurodegenerative Drug Development on Today’s Marketplace
December 5, 2024
Annovis Bio (NYSE: ANVS), a leader in developing treatments for neurodegenerative diseases, was recently featured on Today’s Marketplace in an exclusive interview with Dr. Maria Maccecchini, Founder, President, and CEO. Dr. Maccecchini detailed Annovis Bio’s groundbreaking drug development targeting toxic proteins responsible for nerve cell damage in Alzheimer’s and Parkinson’s, as well as the company’s […]
InvestorNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) CEO Shares Insight on Breakthrough Drug Showing Promise for Neurodegenerative Diseases
December 4, 2024
Annovis Bio (NYSE: ANVS) was featured in an interview with Today’s Marketplace (“TMP”). The company’s Founder, President and CEO, Maria Maccecchini, PHD, and Scott Shipman, MD, MPH, Executive Director for Creighton University’s Institute for Population Health, joined host Jane King to discuss clinical trials of a new drug that is showing promise for the treatment […]
Annovis Bio Inc. (NYSE: ANVS) to Present Recent Achievements and 2025 Strategic Outlook During Upcoming Live Investor Webcast
December 3, 2024
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), will hold a live investor webcast on Dec. 11, 2024, at 4:30 p.m. EST, to provide key operational highlights and year-end clinical updates (https://ibn.fm/69VpQ). The investor webcast will be led […]
Annovis to Host Year-End Investor Webcast on December 11, 2024
November 25, 2024
MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) — via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is pleased to announce a live investor webcast scheduled for December 11, 2024, at 4:30 PM EST. Webcast Details: Dr. Maria Maccecchini, Founder, President, and CEO of Annovis, […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Share Clinical and Strategic Updates
November 25, 2024
Annovis Bio (NYSE: ANVS), a clinical-stage company developing therapies for neurodegenerative diseases, will host a live investor webcast on Dec. 11, 2024, at 4:30 PM EST. Led by Founder and CEO Dr. Maria Maccecchini, the event will highlight updates on Phase 3 studies for Parkinson’s and Alzheimer’s diseases, regulatory milestones, financial strategies, and plans for […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Paving the Way for NDA Submission
November 19, 2024
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on developing transformative therapies for neurodegenerative disorders, including Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), recently achieved a significant milestone in its drug development process. In early October, the company held a meeting with the U.S. Food and Drug Administration (“FDA”), where it received […]
Annovis Bio Inc. (NYSE: ANVS) Concludes Q3 with Strategic Milestones and FDA-Cleared Phase 3 Program for Alzheimer’s Disease
November 13, 2024
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), concluded the third quarter with significant milestones achieved and a clear path forward for its lead candidate, buntanetap. Buntanetap is an innovative drug designed to target neurodegeneration by inhibiting the […]
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)
November 12, 2024
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that its President and CEO, Maria Maccecchini, Ph.D., has been invited to […]
InvestorNewsBreaks – Annovis Bio Inc. CEO to Showcase Buntanetap’s Dual Benefits for Alzheimer’s and Parkinson’s at NIA Workshop
November 12, 2024
Annovis Bio (NYSE: ANVS) announced that its President and CEO, Dr. Maria Maccecchini, will speak at the National Institute on Aging’s (NIA) workshop, “Dementia with Lewy Bodies: Filling the Gaps in Translational and Clinical Research.” Scheduled for Nov. 13, 2024, Dr. Maccecchini’s presentation, titled “One Drug, Dual Effect: Buntanetap Improves Cognitive and Motor Functions, Benefiting […]
InvestorNewsBreaks – Annovis Bio Inc. Advances Alzheimer’s Phase 3 Trials with Strong FDA Support and Financial Backing
November 11, 2024
Annovis Bio (NYSE: ANVS) provided a third-quarter update, announcing significant progress in developing its lead drug candidate, buntanetap, for Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). Following a successful Phase 2 meeting with the FDA, Annovis received clearance to initiate two Phase 3 studies for AD: a six-month trial to evaluate symptomatic relief and an […]
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update
November 11, 2024
MALVERN, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) — via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced financial results for the third quarter ended September 30, 2024, and provided a […]
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Strengthens Clinical Research Team with Appointment of Senior Clinical Scientist
November 7, 2024
Annovis Bio (NYSE: ANVS) has appointed Dr. Matthew Peterson as Senior Clinical Scientist, bolstering the team as it approaches pivotal Phase 3 trials for its neurodegenerative disease therapies, including treatments for Alzheimer’s and Parkinson’s disease. Dr. Peterson, an experienced clinical researcher with a background in both academic and industry roles, joins from Axogen, where he […]
Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist
November 7, 2024
MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) — via IBN — Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson will be responsible […]